Post by Brito1on Oct 30, 2020 2:10pm
255 Views
Post# 31814052
News
News
State of the State... Brilacidin results, SI of 426 (far superior than first hoped for), Free Trials conducted at non-bias RBL's, and the cherry on top ... Dr. William F' DeGrado as your Research and filings and science advocate!!! findings are being submitted for peer-review publication. A preprint, available for download at the link below, is in the process of being posted to bioRxiv.org. Preprint article details research conducted at George Masons Regional Biocontainment Laboratory: A few Highlights: Brilacidin shown in vitro to potently inhibit SARS-CoV-2, the novel coronavirus causing COVID-19. In a human lung cell line infected by SARS-CoV-2, Brilacidin achieved a high Selectivity Index of 426. The primary mechanism of action of Brilacidin appears to disrupt viral integrity and block viral entry. Brilacidin and FDA-approved remdesivir exhibit excellent synergistic activity in vitro against SARS-CoV-2. Preprint: Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2 https://www.ipharminc.com/new-blog/2020/10/30/preprint-brilacidin-a-covid-19-drug-candidate-exhibits-potent-in-vitro-antiviral-activity-against-sars-cov-2 Thanks to Patiencespeople for the great summary